Applications of 'decisionable' biomarkers in cardiovascular drug development. - Wikidata - wikimedia - TriplyDB

Applications of 'decisionable' biomarkers in cardiovascular drug development.

Applications of 'decisionable' biomarkers in cardiovascular drug development.

http://www.wikidata.org/entity/Q37816414

about

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation.

P2860

Q29999973-5FABE0B5-4E2B-41C9-AB42-FDDD25F85503 Q36863958-A7BA6CAA-17F4-44AC-AE51-0EDAA0C9451B

P2860

Applications of 'decisionable' biomarkers in cardiovascular drug development.

http://www.wikidata.org/entity/Q37816414

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Applications of 'decisionable' biomarkers in cardiovascular drug development.

@en

Applications of 'decisionable' biomarkers in cardiovascular drug development.

@nl

type

label

Applications of 'decisionable' biomarkers in cardiovascular drug development.

@en

Applications of 'decisionable' biomarkers in cardiovascular drug development.

@nl

prefLabel

Applications of 'decisionable' biomarkers in cardiovascular drug development.

@en

Applications of 'decisionable' biomarkers in cardiovascular drug development.

@nl

P1433

Q37816414-ED6A7EC1-FE26-48DC-8765-E1D0134AE85B

P1476

Q37816414-A776BF0E-91F2-4547-8800-C4C39A390377

P2093

Q37816414-01850999-D26B-422C-97A8-C8ED56487026

Q37816414-F70CD130-98EB-4C98-9FC2-F60BB8578096

P2860

Q37816414-020697BD-E47C-4701-B79A-2EDE6A5E098D

Q37816414-0614BA77-B3CF-451F-92E1-36B940128F03

Q37816414-0B4EB1AD-295C-4911-8179-A8C6BD6C8CE7

Q37816414-128D3014-5778-4D3B-B632-D533B7E2508C

Q37816414-14BA6F86-B699-4349-82A5-43B88B41C086

Q37816414-1C51F789-68F7-494D-AD27-6A6AFE4F3BB5

Q37816414-2322E3A9-FBD4-47ED-869A-67A9F561296B

Q37816414-249FEE5D-B38A-4E42-AE3E-9D93375D4A48

Q37816414-30F34C94-FEC4-491F-97D0-5A6E25F63FF0

Q37816414-487E5EF1-E4F8-44AF-AAB1-DE7F84713ED9

P304

Q37816414-8F48BCC4-4175-4063-B118-CC36D9BDD382

P31

Q37816414-0F611368-C7AB-419F-9631-061EF2790CE0

Q37816414-130db55d-8a7c-45e6-86cc-e77318059ae0

P356

Q37816414-179FB7FC-72B3-4C0A-9D05-084A89ACEA38

P433

Q37816414-D2C86D3F-CA2D-4B6E-8A02-A25978A4EB30

P478

Q37816414-D5ABD374-C2A5-4370-8D86-359BC6140F15

P577

Q37816414-06FDEB4D-ABC6-4CA9-B7A8-DEE3A0C051A1

P698

Q37816414-91098E76-7090-4B79-B3FD-4A21953AC331

P921

Q37816414-EF01A7F3-E567-4742-8ED5-E61FC982C82B

P356

P1433

Biomarkers in Medicine

P1476

Applications of 'decisionable' biomarkers in cardiovascular drug development.

@en

P2093

John A Wagner

http://www.w3.org/2001/XMLSchema#string

Rajesh Krishna

http://www.w3.org/2001/XMLSchema#string

P2860

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

Effect of torcetrapib on the progression of coronary atherosclerosis

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

P304

815-827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/BMM.10.107

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21133701

http://www.w3.org/2001/XMLSchema#string

P921